GW's Epidiolex Epilepsy Data Paves Way For Cannabinoids

25 May 2017

• By Emily Hayes

Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.

The positive reception of Phase III data for GW Pharmaceuticals PLC's cannabinoid therapy Epidiolex for Dravet syndrome, a severe type of pediatric epilepsy, in the New England Journal of Medicine is an important step for pharmaceutical-grade cannabinoids as a therapeutic option for neurological disorders as well as other diseases.

Derived from the marijuana plant, Epidiolex includes cannabidiol (CBD) but not the psychoactive tetrahydrocannabinol (THC). The drug is one of over 50 cannabinoids in any stage of development, according to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Angelini Advances Brain Health Ambitions With GRIN Pact

27 May 2025

• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

22 May 2025

• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

16 May 2025

• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.